Sandoz
Sandoz’s Subdued Market Entrance After Splitting from Novartis
Sandoz has successfully completed its separation from Novartis after extensive preparations lasting over a year. However, the initial valuation on ...
Sandoz gets CHMP nod for biosimilar of Herceptin, a drug for HER2+ breast and gastric cancer
Sandoz, a leading global player in generic and biosimilar medications, has received a noteworthy endorsement from the Committee for Medicinal ...
Sandoz to market Samsung Bioepisā biosimilar of Stelara in US and Canada
Sandoz is expanding its biosimilar portfolio by signing a commercialization agreement with Samsung Bioepis for a biosimilar version of Johnson ...
Sandoz Acquires Mycamine, a Top Antifungal Drug, from Astellas
In the ever-evolving landscape of medical advancements, Sandoz emerges as a dominant force, orchestrating a strategic move that echoes across ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Novartis Nears Sandoz Spinoff Milestone with Unique Stock Distribution Strategy
As the long-anticipated spinoff of Novartis’ Sandoz division draws near, the Swiss pharmaceutical giant has unveiled a novel approach to ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
Sandoz’s Biosimilar Natalizumab Receives Positive CHMP Opinion for Multiple Sclerosis Treatment
Source – Novartis On July 24, 2023 Sandoz announced a significant milestone. The Committee for Medicinal Products for Human Use ...
Sandoz Plans Biosimilar Technical Development Centre in Slovenia for Future Pipeline Expansion
Source – Novartis July 20, 2023, Sandoz, a renowned global leader in generic and biosimilar medicines, has disclosed a substantial ...
Novartis Announces Strong Revenue Growth, Share Buyback, and Sandoz Separation
Source – Novartis Novartis, a pharmaceutical company, has announced a new $15 billion stock repurchase plan after completing a previous ...
Sandoz Enters US Immunology Market with Launch of High-Concentration Formulation Hyrimoz
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection ...
To speed up patient access to Biosimilar medications, Sandoz announces the Act4 Biosimilars Action Plan
Source – Novartis On June 15, a global plan to improve patient access to biologic medicines was launched, according to ...
Sandoz Aims for Success in Biosimilars, Forecasts $3 Billion in Sales from Pipeline Products in Next 5 Years
Sandoz, the generics and biosimilars division of Novartis, is set to become an independent company and is determined to reverse ...
